The project goals are 1) to develop biocompatible nanoparticles (NP) bearing Pattern Recognition Receptor (PRR) molecules, i.e., agonists for Toll Like Receptors or C-type Lectin Receptors, 2) to determine if these NP- PRR differently affect activation of dendritic cells (DC), 3) to determine if the differently activated DC then influence the generation and functionality of T effector cells, and 4) to evaluate the alloreactive CTL and the autologous tumor associated antigen (TAA)-directed CTL in the GL261 mouse glioma model, where the tumor cell inoculum either is or is not enriched for brain tumor stem cells (BTSC). The latter goal will allow for a determination of BTSC immunosensitivity/immunoresistance. The cancer immunotherapy approach will: """"""""Use various NP-PRR (CpG DNA, imiquimod, LPS and mannosylated BSA) that will be components of a biocompatible PLGA carrier matrix already approved for clinical use to stimulate DC to variable activation states. In some experiments complex NP-PRR will also contain tumor associated antigens (mEphA2, hgp100, mTRP-2 and GARC-1) """""""" Use conventional and Flt3 ligand DC derived from immature bone marrow (BM) as precursor cells """""""" NP-PRR activated DC will then be used to stimulate alloreactive or autologous naive T cells to effector cytotoxic T lymphocytes (CTL) """"""""NP-PRR stimulated DC and subsequently stimulated CTL will be functionally and phenotypically characterized in vitro.""""""""Stimulated alloreactive CTL or TAA-directed CTL will be functionally and phenotypically characterized for their antitumor effects after their adoptive transfer into mice bearing serum-cultured GL261 or the neurosphere-cultured counterpart.

Public Health Relevance

The work proposed here is an interdisciplinary project in translational medicine that brings together several key elements: 1. Cytotoxic T Lymphocytes (CTL)-effector cells for immunotherapy 2. Dendritic Cells (DC)-antigen presenting cells (APC) used to induce CTL effectors in vitro 3. Nanoparticles (NP) and their payload-activation stimuli and antigens delivered to DC 4. Brain Tumor Stem Cells (BTSC)-therapy-resistant tumor cells that should be included as targets of the effector cells The goal of this project is to modulate dendritic cell activation with pathogen associated signaling molecules contained with nanoparticles. These nanoparticles will be used to stimulate dendritic cells to various activation states. The dendritic cells will then be used to stimulate naive T cells into effector cells. The generated CTL will be functionally and phenotypically characterized in vitro and in vivo using mouse glioma cell targets or those enriched for brain tumor stem cells in culture.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA154256-04
Application #
8515755
Study Section
Special Emphasis Panel (ZRG1-BDCN-W (02))
Program Officer
Welch, Anthony R
Project Start
2010-07-13
Project End
2015-05-31
Budget Start
2013-07-19
Budget End
2014-05-31
Support Year
4
Fiscal Year
2013
Total Cost
$370,764
Indirect Cost
$130,008
Name
University of California Los Angeles
Department
Neurosurgery
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Antonios, Joseph P; Soto, Horacio; Everson, Richard G et al. (2017) Detection of immune responses after immunotherapy in glioblastoma using PET and MRI. Proc Natl Acad Sci U S A 114:10220-10225
Kilinc, Mehmet Okyay; Ehrig, Klaas; Pessian, Maysam et al. (2016) Colonization of xenograft tumors by oncolytic vaccinia virus (VACV) results in enhanced tumor killing due to the involvement of myeloid cells. J Transl Med 14:340
Antonios, Joseph P; Soto, Horacio; Everson, Richard G et al. (2016) PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight 1:
Everson, Richard G; Antonios, Joseph P; Lisiero, Dominique N et al. (2016) Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma. Neuro Oncol 18:368-78
Hsu, Melody; Sedighim, Shaina; Wang, Tina et al. (2016) TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC Vaccination. Cancer Immunol Res 4:412-418
Hoa, Neil T; Ge, Lisheng; Erickson, Kate L et al. (2015) Fascin-1 knock-down of human glioma cells reduces their microvilli/filopodia while improving their susceptibility to lymphocyte-mediated cytotoxicity. Am J Transl Res 7:271-84
Owens, Geoffrey C; Erickson, Kate L; Malone, Colin C et al. (2015) Evidence for the involvement of gamma delta T cells in the immune response in Rasmussen encephalitis. J Neuroinflammation 12:134
Erickson, Kate L; Hickey, Michelle J; Kato, Yuki et al. (2015) Radial mobility and cytotoxic function of retroviral replicating vector transduced, non-adherent alloresponsive T lymphocytes. J Vis Exp :
Varadkar, Sophia; Bien, Christian G; Kruse, Carol A et al. (2014) Rasmussen's encephalitis: clinical features, pathobiology, and treatment advances. Lancet Neurol 13:195-205
Owens, Geoffrey C; Huynh, My N; Chang, Julia W et al. (2013) Differential expression of interferon-ýý and chemokine genes distinguishes Rasmussen encephalitis from cortical dysplasia and provides evidence for an early Th1 immune response. J Neuroinflammation 10:56

Showing the most recent 10 out of 21 publications